These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 28833362)

  • 1. Evaluation of Progesterone Utilization and Birth Outcomes in a State Medicaid Plan.
    Hydery T; Price MK; Greenwood BC; Takeshita M; Kunte PS; Mauro RP; Lenz K; Jeffrey PL
    Pharmacotherapy; 2017 Oct; 37(10):1328-1334. PubMed ID: 28833362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of response to 17-alpha hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth.
    Manuck TA; Esplin MS; Biggio J; Bukowski R; Parry S; Zhang H; Huang H; Varner MW; Andrews W; Saade G; Sadovsky Y; Reddy UM; Ilekis J;
    Am J Obstet Gynecol; 2016 Mar; 214(3):376.e1-8. PubMed ID: 26692181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 17-alpha Hydroxyprogesterone caproate did not reduce the rate of recurrent preterm birth in a prospective cohort study.
    Nelson DB; McIntire DD; McDonald J; Gard J; Turrichi P; Leveno KJ
    Am J Obstet Gynecol; 2017 Jun; 216(6):600.e1-600.e9. PubMed ID: 28223163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of preterm birth with vaginal progesterone or 17-alpha-hydroxyprogesterone caproate: a critical examination of efficacy and safety.
    O'Brien JM; Lewis DF
    Am J Obstet Gynecol; 2016 Jan; 214(1):45-56. PubMed ID: 26558340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pregnancy outcomes of managed Medicaid members prescribed home administration of 17 α-hydroxyprogesterone caproate.
    Lucas B; Poole-Yaeger A; Istwan N; Stanziano G; Rhea D; Mason M
    Am J Perinatol; 2012 Aug; 29(7):489-96. PubMed ID: 22399213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adherence rates and outcomes for 17-hydroxyprogesterone caproate use in women with a previous history of preterm birth.
    Edwards AM; Lowry SA; Mikovich S; Forinash AB; Babbar S
    Am J Obstet Gynecol MFM; 2020 Aug; 2(3):100166. PubMed ID: 33345885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of Cervical Cerclage and Vaginal Progesterone in the Treatment of Cervical Incompetence with/without Preterm Birth History.
    Wang SW; Ma LL; Huang S; Liang L; Zhang JR
    Chin Med J (Engl); 2016 Nov; 129(22):2670-2675. PubMed ID: 27823998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of 17P usage on NICU admissions in a managed medicaid population--a five-year review.
    Mason MV; Poole-Yaeger A; Krueger CR; House KM; Lucas B
    Manag Care; 2010 Feb; 19(2):46-52. PubMed ID: 20550052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 17-alpha-hydroxyprogesterone caproate versus vaginal progesterone suppository for the prevention of preterm birth in women with a sonographically short cervix: A randomized controlled trial.
    Pirjani R; Heidari R; Rahimi-Foroushani A; Bayesh S; Esmailzadeh A
    J Obstet Gynaecol Res; 2017 Jan; 43(1):57-64. PubMed ID: 27775195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does adjunctive use of progesterone in women with cerclage improve prevention of preterm birth?
    Sinkey RG; Garcia MR; Odibo AO
    J Matern Fetal Neonatal Med; 2018 Jan; 31(2):202-208. PubMed ID: 28068860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relation of body mass index to frequency of recurrent preterm birth in women treated with 17-alpha hydroxyprogesterone caproate.
    Co AL; Walker HC; Hade EM; Iams JD
    Am J Obstet Gynecol; 2015 Aug; 213(2):233.e1-5. PubMed ID: 25912300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Variation in Coverage for Progesterone to Prevent Preterm Birth: A Survey of Medicaid Managed Care Organizations.
    Batra P; Hernandez Gray AA; Moore JE
    Womens Health Issues; 2017; 27(5):573-578. PubMed ID: 28687440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 17-Hydroxyprogesterone caproate (17OHP-C) coverage among eligible women delivering at 2 North Carolina hospitals in 2012 and 2013: A retrospective cohort study.
    Stringer EM; Vladutiu CJ; Manuck T; Verbiest S; Ollendorff A; Stringer JS; Menard MK
    Am J Obstet Gynecol; 2016 Jul; 215(1):105.e1-105.e12. PubMed ID: 26829508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of partial compliance on the prevention of recurrent preterm birth in women receiving weekly 17 alpha-hydroxyprogesterone caproate injections.
    Haidar ZA; Moussa HN; Hosseini Nasab S; Sibai BM
    J Matern Fetal Neonatal Med; 2017 Dec; 30(24):2926-2932. PubMed ID: 27921517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 17α-hydroxyprogesterone caproate access in the Louisiana Medicaid population.
    Orsulak MK; Block-Abraham D; Gee RE
    Clin Ther; 2015 Apr; 37(4):727-32. PubMed ID: 25700945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 17alpha-hydroxyprogesterone caproate for the prevention of preterm delivery: A cost-effectiveness analysis.
    Odibo AO; Stamilio DM; Macones GA; Polsky D
    Obstet Gynecol; 2006 Sep; 108(3 Pt 1):492-9. PubMed ID: 16946206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal routes of administration, vehicles and timing of progesterone treatment for inhibition of delivery during pregnancy.
    Fang D; Moreno M; Garfield RE; Kuon R; Xia H
    Eur J Obstet Gynecol Reprod Biol; 2017 Sep; 216():164-168. PubMed ID: 28777967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utilization of hydroxyprogesterone caproate among pregnancies with live birth deliveries in the sentinel distributed database.
    Shinde M; Cosgrove A; Woods CM; Chang C; Nguyen CP; Moeny D; Ajao A; Kolonoski J; Tsai HT
    J Matern Fetal Neonatal Med; 2022 Dec; 35(25):6291-6296. PubMed ID: 33926341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Application of Progesterone for the Prevention of Preterm Birth, 2016.
    Goodnight W
    Am J Perinatol; 2016 Feb; 33(3):253-7. PubMed ID: 26788788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized controlled trial of intramuscular versus vaginal progesterone for the prevention of recurrent preterm birth.
    Elimian A; Smith K; Williams M; Knudtson E; Goodman JR; Escobedo MB
    Int J Gynaecol Obstet; 2016 Aug; 134(2):169-72. PubMed ID: 27168167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.